Incidence of dravet syndrome in a US population

Pediatrics

Volumn 136, Issue 5, 2015, Pages e1310-e1315

  Wu, Yvonne W ^a   Sullivan, Joseph ^a   McDaniel, Sharon S ^b   Meisler, Miriam H ^c   Walsh, Eileen M ^d   Li, Sherian Xu ^d   Kuzniewicz, Michael W ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Divisions of Child Neurology   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d University of Michigan ^*  (United States)

^e KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; METHYL CPG BINDING PROTEIN 2; SODIUM CHANNEL NAV1.1; SCN1A PROTEIN, HUMAN;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ETHNICITY; GENE; GENE DELETION; GENE IDENTIFICATION; GENETIC RISK; GENETIC VARIABILITY; HIGH RISK INFANT; HUMAN; INCIDENCE; INFANT; MECP2 GENE; MEDICAL RECORD REVIEW; MISSENSE MUTATION; MUTATIONAL ANALYSIS; MYOCLONUS SEIZURE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POLG GENE; PRIORITY JOURNAL; RISK ASSESSMENT; SCN1A GENE; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; TONIC CLONIC SEIZURE; UNITED STATES; CALIFORNIA; EPILEPSIES, MYOCLONIC; FEMALE; GENETICS; MALE; RETROSPECTIVE STUDY;

CALIFORNIA; EPILEPSIES, MYOCLONIC; FEMALE; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MUTATION, MISSENSE; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; RETROSPECTIVE STUDIES;

EID: 84947253588     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2015-1807     Document Type: Article

References (38)

1. Brunklaus A, Dorris L, Zuberi SM. Comorbidities and predictors of health-related quality of life in Dravet syndrome. Epilepsia. 2011;52(8):1476-1482
2. Ragona F, Brazzo D, De Giorgi I, et al. Dravet syndrome: early clinical manifestations and cognitive outcome in 37 Italian patients. Brain Dev. 2010;32(1):71-77
3. Ragona F, Granata T, Dalla Bernardina B, et al. Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients. Epilepsia. 2011;52(2):386-392
4. Escayg A, Goldin AL. Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia. 2010;51(9):1650-1658
5. Fukuma G, Oguni H, Shirasaka Y, et al. Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB). Epilepsia. 2004;45(2):140-148
6. Wang JW, Kurahashi H, Ishii A, et al. Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. Epilepsia. 2008;49(9):1528-1534
7. Zuberi SM, Brunklaus A, Birch R, Reavey E, Duncan J, Forbes GH. Genotype-phenotype associations in SCN1A-related epilepsies. Neurology. 2011;76(7):594-600
8. Brunklaus A, Dorris L, Ellis R, et al. The clinical utility of an SCN1A genetic diagnosis in infantile-onset epilepsy. Dev Med Child Neurol. 2013;55(2):154-161
9. Ceulemans B, Boel M, Claes L, et al. Severe myoclonic epilepsy in infancy: toward an optimal treatment. J Child Neurol. 2004;19(7):516-521
10. Hattori J, Ouchida M, Ono J, et al. A screening test for the prediction of Dravet syndrome before one year of age. Epilepsia. 2008;49(4):626-633
11. Specchio N, Balestri M, Trivisano M, et al. Electroencephalographic features in Dravet syndrome: five-year follow-up study in 22 patients. J Child Neurol. 2012;27(4):439-444
12. Striano P, Striano S, Minetti C, Zara F. Refractory, life-threatening status epilepticus in a 3-year-old girl. Lancet Neurol. 2008;7(3):278-284
13. Hurst DL. Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia. 1990;31(4):397-400
14. Rosander C, Hallböök T. Dravet syndrome in Sweden: a population-based study. Dev Med Child Neurol. 2015;57(Mar):628-634
15. Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135(pt 8):2329-2336
16. Bayat A, Hjalgrim H, Møller RS. The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22, 000: a population-based study from 2004 to 2009. Epilepsia. 2015;56(4):e36-e39
17. Adzhubei I, Jordan DM, Sunyaev S.R. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;76(7.20):1-7
18. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7): 1073-1081
19. GeneTests. epiSEEK Comprehensive Sequence Analysis for Epilepsy and Seizure Disorders. Available at: https://www.genetests.org/tests/details.php?id= 150198. Accessed August 8, 2015
20. Meng H, Xu HQ, Yu L, et al. The SCN1A mutation database: updating information and analysis of the relationships among genotype, functional alteration, and phenotype. Hum Mutat. 2015;36(6): 573-580
21. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39(5):508-512
22. Kassaï B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49(2):343-348
23. Chiron C, Marchand MC, Tran A, et al; STICLO Study Group. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet. 2000; 356(9242):1638-1642
24. Kröll-Seger J, Portilla P, Dulac O, Chiron C. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics. 2006;37(6):325-329
25. Chipaux M, Villeneuve N, Sabouraud P, et al. Unusual consequences of status epilepticus in Dravet syndrome. Seizure. 2010;19(3):190-194
26. Okumura A, Uematsu M, Imataka G, et al. Acute encephalopathy in children with Dravet syndrome. Epilepsia. 2012;53(1):79-86
27. Escayg A, Heils A, MacDonald BT, Haug K, Sander T, Meisler MH. A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus-and prevalence of variants in patients with epilepsy. Am J Hum Genet. 2001;68(4): 866-873
28. Wallace RH, Scheffer IE, Barnett S, et al. Neuronal sodium-channel alpha1-subunit mutations in generalized epilepsy with febrile seizures plus. Am J Hum Genet. 2001;68(4):859-865
29. Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006;9(9): 1142-1149
30. Ogiwara I, Miyamoto H, Morita N, et al. Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci. 2007; 27(22):5903-5914
31. Liu Y, Lopez-Santiago LF, Yuan Y, et al. Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. Ann Neurol. 2013;74(1):128-139
32. Patino GA, Claes LR, Lopez-Santiago LF, et al. A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci. 2009;29(34): 10764-10778
33. Carvill GL, Weckhuysen S, McMahon JM, et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology. 2014;82(14):1245-1253
34. Wagnon JL, Meisler MH. Recurrent and non-recurrent mutations of SCN8A in epileptic encephalopathy. Front Neurol. 2015;6(104):1-6
35. Meisler MH, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest. 2005;115(8):2010-2017
36. Volkers L, Kahlig KM, Verbeek NE, et al. Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or Dravet syndrome. Eur J Neurosci. 2011;34(8): 1268-1275
37. Harkin LA, McMahon JM, Iona X, et al; Infantile Epileptic Encephalopathy Referral Consortium. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain. 2007;130(pt 3): 843-852
38. Depienne C, Trouillard O, Saint-Martin C, et al. Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients. J Med Genet. 2009;46(3):183-191